Core Viewpoint - Guangdong Guanghua Technology Co., Ltd. has announced the change of its signing accountants, confirming the appointment of the new signing accountants for the 2024 annual audit [1]. Group 1: Announcement of Accountant Change - The company held meetings on April 26, 2024, and approved the proposal to reappoint Zhonghua Accounting Firm as the auditing institution for the 2024 fiscal year [1]. - The signing accountants have been changed from Wang Penglin and Xu Xirui to Kuai Yiyi and Xu Xirui, with the latter continuing to provide services for the annual audit [1]. Group 2: Information on New Signing Accountant - Kuai Yiyi has been engaged in auditing since 2005, with over 19 years of experience in securities services and has been a registered accountant since March 2008 [2]. - Kuai Yiyi has not faced any criminal penalties or administrative sanctions from regulatory bodies in the past three years [2]. - There are no independence issues concerning Kuai Yiyi as per the Code of Ethics for Chinese Certified Public Accountants [3]. Group 3: Transition and Impact - The transition of responsibilities during the change of signing accountants has been orderly, and it is stated that this change will not affect the audit of the company's 2024 annual financial statements and internal controls [4].

证券代码：002741 证券简称：光华科技 公告编号：2025-016 广东光华科技股份有限公司 关于变更签字会计师的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 广东光华科技股份有限公司（以下简称"公司"）2024 年 4 月 26 日召开第 五届董事会第十二次会议、第五届监事会第十一次会议审议通过了《关于续聘会 计师事务所的议案》，于 2024 年 5 月 17 日召开 2023 年年度股东大会，审议通 过了《关于续聘会计师事务所的议案》，同意公司续聘众华会计师事务所（特殊 普通合伙）（以下简称"众华所"）为公司 2024 年度审计机构。具体内容分别 详见公司 2024 年 4 月 27 日、2024 年 5 月 18 日在本公司指定信息披露网站巨潮 资讯网（www.cninfo.com.cn）刊登的《关于续聘会计师事务所的公告》。 公司于近日收到众华会计师事务所（特殊普通合伙）出具的《关于委派广东 光华科技股份有限公司签字注册会计师的说明函》，具体情况公告如下： 一、签字会计师变更情况 众华会计师事务所（特殊普通合伙）作为公司 2024 年年度 ...

证券代码：002741 证券简称：光华科技 公告编号：2025-015 广东光华科技股份有限公司 关于控股股东、实际控制人增持计划期限届满暨 实施完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、增持计划基本情况：广东光华科技股份有限公司（以下简称"公司"）于 2024 年 10 月 12 日披露了《关于控股股东、实际控制人增持公司股份计划的公 告》（公告编号：2024-030），控股股东、实际控制人郑靭先生（以下统称"增持 主体"）计划自 2024 年 10 月 14 日起 6 个月内，使用自有资金或自筹资金通过 深圳证券交易所交易系统允许的方式（包括但不限于集中竞价和大宗交易）增持 公司股票，本次增持不设增持股份价格的上限及下限，拟增持股数自 100 万股起。 2、目前增持计划实施期限届满，本次增持计划的实施期间，控股股东、实 际控制人郑靭先生通过深圳证券交易所交易系统集中竞价方式增持公司股份 100 万股，增持金额合计 1739.08 万元。 一、增持主体的基本情况 1、增持主体：公司控股股东、实际控制人、总经理郑靭先生。 2 ...

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

特别提示：本公告所载2024年度的财务数据仅为初步核算数据，未经会计师事务所审计，与年度报告中 披露的最终数据可能存在差异，请投资者注意投资风险。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002741 证券简称：光华科技 公告编号：2025-013 广东光华科技股份有限公司 2024年度业绩快报 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、2024年度主要财务数据和指标 单位：万元 ■ 二、经营业绩和财务状况情况说明 （一）经营业绩、财务状况 2024 年度公司实现营业收入258,900.78万元，同比减少4.09%；归属于上市公司股东的净利润-20,494.72 万元，同比减亏52.42%，扣除非经常性损益后的归属于上市公司股东的净利润-16,407.21万元，同比减 亏62.04%。 （二）影响经营业绩的主要因素 受行业周期性波动影响，新能源材料订单需求不足，碳酸锂等产品价格持续低位，新能源材料板块获利 能力继续下降，导致经营亏损。另公司根据《企业会计准则》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指南 ...

Group 1: Company Announcements - China Pacific Insurance (China Life) expects a net profit increase of 30% to 50% for Q1 2025, projecting a profit range of 11.652 billion to 13.445 billion yuan [2] - New Lai Fu plans to acquire 100% equity of Guangzhou Jin Nan Magnetic Materials, with trading suspension starting from April 14, 2025, due to significant asset restructuring [3] - Jiangling Motors intends to repurchase A-shares with a total fund of no less than 1.5 billion and no more than 2 billion yuan, at a price not exceeding 22.00 yuan per share [4] - Guanghua Technology anticipates a net profit increase of 479.25% to 637.23% for Q1 2025, estimating a profit range of 22 million to 28 million yuan [7] - Starhua New Materials reported a net profit of 148 million yuan for 2024, with a year-on-year increase of 51.93%, and plans to distribute a cash dividend of 8 yuan per 10 shares [10] Group 2: Clinical Trial Approvals - Heng Rui Pharmaceutical received approval for clinical trials of HRS-9190, a new drug for anesthesia, and SHR-3792, an innovative anti-tumor candidate, with no similar drugs approved in the market [1]

Group 1: Company Performance - Guanghua Technology expects a net profit growth of 479% to 637% year-on-year for Q1 2025, with an estimated profit of 22 million to 28 million yuan, driven by business expansion in specialized chemicals and cost reduction measures [1] - China Pacific Insurance anticipates a net profit increase of 30% to 50% year-on-year for Q1 2025, projecting a profit of 11.652 billion to 13.445 billion yuan, attributed to improved business quality and significant investment performance [2] - Zhenyu Technology forecasts a net profit growth of 31.54% to 42.97% year-on-year for Q1 2025, estimating a profit of 69 million to 75 million yuan, supported by increased sales orders and enhanced production automation [7] - Chuangjiang New Materials expects a net profit increase of 26.74% to 46.24% year-on-year for Q1 2025, with an estimated profit of 130 million to 150 million yuan, driven by stable growth in production and sales [8] Group 2: Corporate Actions - Xinlaifu plans to acquire 100% equity of Guangzhou Jinnan Magnetic Materials, leading to a significant asset restructuring, with trading suspended from April 14, 2025 [2] - Jiangling Motors intends to repurchase A-shares worth 150 million to 200 million yuan for employee stock ownership plans or equity incentives [5] - Yingfeite plans to repurchase shares worth 50 million to 100 million yuan for employee stock ownership or equity incentive plans [6] - Guanghua Technology's major shareholder is undergoing a change in its upper equity structure, but the actual controller remains the Zhuhai State-owned Assets Supervision and Administration Commission [4] Group 3: Regulatory Approvals - Hengrui Medicine received approval for clinical trials of its new drug HRS-9190, which is intended for use during anesthesia induction and maintenance [9]

4月13日晚间光华科技（002741）披露了2024年业绩快报及2025一季度业绩预告。 根据披露的调整方案，光华科技综合考量新能源材料生产原材料供应及能源成本等关键因素，为进一步 强化产业链上下游稳定协同合作关系，公司计划通过合理调整生产基地的布局，对产业链进行优化，有 效降低生产成本，提高公司新能源产品的综合竞争力。 同时，鉴于对新能源材料板块布局及生产计划调整，涉及部分设备设施将停止运行或出售，公司对该调 整涉及的各项长期资产进行了减值测试，根据测试结果及会计准则规定充分计提减值准备，真实反映资 产的公允价值。 该公司表示，本次调整是公司根据市场变化及实际经营发展需要做出的积极应对，契合公司未来业务拓 展需要，公司通过重新规划各项资产的使用方案，实现资产利用率的最大化，为公司持续健康发展提供 有力支撑。 2024年，光华科技实现营业收入25.89亿元，同比减少4.09%；归属净利润-2.05亿元，同比减亏52.42%， 扣非净利润-1.64亿元，同比减亏62.04%。 对于2024年业绩表现，光华科技表示，受行业周期性波动影响，新能源材料订单需求不足，碳酸锂等产 品价格持续低位，新能源材料板块获利能力继 ...

Core Viewpoint - Guanghua Technology (002741) expects a significant increase in net profit for Q1 2025, projecting a net profit attributable to shareholders of 22 million to 28 million yuan, representing an increase of 479.25% to 637.23% compared to the same period last year [1] Financial Performance - The expected net profit after deducting non-recurring gains and losses is projected to be between 17.95 million and 23.95 million yuan, which is an increase of 639.87% to 887.18% year-on-year [1] - The basic earnings per share are anticipated to be between 0.05 yuan and 0.06 yuan [1] Business Strategy - The company continues to strengthen its efforts in expanding the specialized chemical products segment, aiming to break through key benchmark customers in the industry [1] - There is a focus on cost reduction and efficiency improvement to enhance product competitiveness and operational efficiency [1]

[Key Financial Data and Indicators](index=1&type=section&id=Item%201.%20Key%20Financial%20Data%20and%20Indicators) The company's 2024 total operating revenue decreased by 4.09%, yet net loss attributable to shareholders significantly narrowed by 52.42%, with period-end total assets and equity showing growth Key Financial Data and Indicators | Item | Current Period | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | **Operating Performance** | | | | | Total Operating Revenue (million yuan) | 2,589.01 | 2,699.46 | -4.09 | | Operating Profit (million yuan) | -183.59 | -510.46 | 64.03 | | Total Profit (million yuan) | -201.34 | -516.20 | 61.00 | | Net Profit Attributable to Shareholders (million yuan) | -204.95 | -430.71 | 52.42 | | Net Profit Attributable to Shareholders (Excl. Non-recurring Items) (million yuan) | -164.07 | -432.22 | 62.04 | | Basic Earnings Per Share (yuan) | -0.51 | -1.08 | 52.78 | | **Financial Position (Period-End)** | **Current Period-End** | **Prior Period-End** | **Change (%)** | | Total Assets (million yuan) | 3,511.24 | 3,242.06 | 8.30 | | Owners' Equity Attributable to Shareholders (million yuan) | 1,832.39 | 1,347.43 | 35.99 | | Share Capital (million yuan) | 465.02 | 399.48 | 16.41 | | Net Assets Per Share Attributable to Shareholders (yuan) | 3.94 | 3.37 | 16.91 | [Explanation of Operating Performance and Financial Position](index=1&type=section&id=Item%202.%20Explanation%20of%20Operating%20Performance%20and%20Financial%20Position) The company's 2024 loss is primarily due to the new energy materials segment's reduced profitability from market downturns and low product prices, compounded by significant asset impairment and disposal losses - In 2024, the company achieved total operating revenue of **2.589 billion yuan**, a **4.09%** year-on-year decrease; net profit attributable to shareholders was **-205 million yuan**, representing a **52.42%** reduction in loss year-on-year[5](index=5&type=chunk)[6](index=6&type=chunk) - The primary reason for the performance loss is the new energy materials segment's reduced profitability due to industry cyclical fluctuations, insufficient order demand, and persistently low prices for products like lithium carbonate[7](index=7&type=chunk) - The company recognized approximately **140 million yuan** in impairment provisions for long-term assets related to the new energy materials segment and approximately **24.2 million yuan** in long-term asset disposal losses, negatively impacting current period profit[7](index=7&type=chunk) [Explanation of Differences from Previous Performance Forecast](index=2&type=section&id=Item%203.%20Explanation%20of%20Differences%20from%20Previous%20Performance%20Forecast) The net profit data in this performance express report shows no significant difference from the previous forecast, with only a reclassification of asset impairment during audit not impacting key financial totals - Preliminary calculations indicate no significant difference between the 2024 net profit attributable to shareholders and the previously disclosed performance forecast data[8](index=8&type=chunk) - During the annual audit, following communication with the accounting firm, the company reclassified asset impairment items originally recorded as non-recurring gains/losses to recurring gains/losses, an adjustment that does not affect total revenue, total profit, or total assets[8](index=8&type=chunk) [Other Explanations and Reference Documents](index=2&type=section&id=Item%204.%20Other%20Explanations) This performance express report contains preliminary, unaudited financial results, with final data subject to the audited 2024 annual report, and investors should be aware of investment risks - This performance express report represents preliminary calculations by the company's finance department, with final financial data subject to the audited 2024 annual report, and investors are reminded to be aware of investment risks[9](index=9&type=chunk) - Reference documents include comparative balance sheets and income statements signed and sealed by the company's legal representative, chief financial officer, and head of accounting[10](index=10&type=chunk)